Importance of bone assessment and prevention of osteoporotic fracture in patients with prostate cancer in the gonadotropic hormone analogues use

Bruno Lopes Cançado; Luiz Carlos Miranda; Miguel Madeira; Maria Lucia Fleiuss Farias

doi:10.1590/0100-69912015001012

Importance of bone assessment and prevention of osteoporotic fracture in patients with prostate cancer in the gonadotropic hormone analogues use

Rev Col Bras Cir. 2015 Jan-Feb;42(1):62-6. doi: 10.1590/0100-69912015001012.

[Article in English, Portuguese]

Authors

Bruno Lopes Cançado¹, Luiz Carlos Miranda¹, Miguel Madeira², Maria Lucia Fleiuss Farias²

Affiliations

¹ Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
² Departament of Endocrinology, Faculty of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

PMID: 25992703
DOI: 10.1590/0100-69912015001012

Abstract

The antiandrogenic therapy (ADT) for prostate cancer represents an additional risk factor for the development of osteoporosis and fragility fractures. Still, bone health of patients on ADT is often not evaluated. After literature research we found that simple preventive measures can prevent bone loss in these patients, resulting in more cost-effective solutions to the public health system and family when compared to the treatment of fractures.

Publication types

Review

MeSH terms

Androgen Antagonists / adverse effects*
Androgen Antagonists / therapeutic use
Gonadotropin-Releasing Hormone / analogs & derivatives*
Humans
Male
Osteoporotic Fractures / chemically induced*
Osteoporotic Fractures / prevention & control*
Prostatic Neoplasms / drug therapy*

Substances

Androgen Antagonists
Gonadotropin-Releasing Hormone